UK uses an untested strategy to rapidly but partially protect people at risk

With the virus running amok in the country and vaccines in short-supply, the U.K. is attempting an untested strategy of delaying the second dose of both AstraZeneca and Pfizer vaccine even in the absence of data from large trials. The intent is to rapidly but partially protect more individuals who are at risk.

Advertisement

Can COVID-19 vaccines with EUA be used at the population level?

Emergency use approval is given during public health emergencies and that emergency is the same for everyone, countries have identified high-risk groups that will receive the vaccine first. If and when vaccines from many manufacturers become available, can it be used at the population level even when they have only an emergency use approval is … Continue reading Can COVID-19 vaccines with EUA be used at the population level?

By putting the vaccine approval on hold for want of data, DCGI has underscored its priorities

With a single stroke of a pen, the Drugs Controller General of India has put to rest any doubts and concerns that it would rush to grant emergency use approval to COVID-19 vaccines tested and manufactured in India or elsewhere in the absence of supporting data. With a single stroke of a pen, the Drugs … Continue reading By putting the vaccine approval on hold for want of data, DCGI has underscored its priorities

Transparency in COVID-19 vaccine trials vital to gain public trust

Even as announcing sketchy results of vaccine trials through press releases has become the troubling norm during the pandemic, Serum Institute has moved further down on the transparency scale even as the company seeks an emergency use approval. The Pune-based vaccine manufacturer has so far not shared any information about vaccine safety and efficacy even … Continue reading Transparency in COVID-19 vaccine trials vital to gain public trust

COVID-19: Challenges in achieving herd immunity through vaccination

Where everyone is equally affected by COVID-19 disease, immunisation should be available to all when vaccines are ready. It is important to remember that vaccines are a tool to promote health equity. If the goal is to achieve herd immunity, we will need about 70% of the population to be covered. Breaking the chain of … Continue reading COVID-19: Challenges in achieving herd immunity through vaccination

Oxford vaccine shows 90% efficacy in Phase-3 trial

Interim data analysis of Phase-3 trial of Oxford/AstraZeneca COVID-19 candidate vaccine (ChAdOx1 nCoV-2019) showed different efficacies in preventing COVID-19 disease. In the case of the regimen where a halved dose was used as a prime (first dose) followed by a standard dose of booster, the efficacy was 90%. However, when full doses (standard doses) were … Continue reading Oxford vaccine shows 90% efficacy in Phase-3 trial

Oxford vaccine found safe and immunogenic even in older adults

Results of the Phase-2 trial of the Oxford vaccine show that the vaccine is safe across age groups — younger (18-55 years age) and older adults (over 56 years age). In fact, older adults better tolerated the vaccine than younger adults, the results show. The vaccine also induced T cell immune responses and neutralising antibodies … Continue reading Oxford vaccine found safe and immunogenic even in older adults

Pfizer’s COVID-19 vaccine shows promise, many unknowns remain

The over 90% effectiveness reported is basically against symptomatic infection. But the nature of infection — mild, moderate or severe — that the vaccine can protect against is not clear. It is also unclear if the vaccinated participants have been asymptomatically infected and whether older adults were protected. The first interim analysis of the Phase-3 … Continue reading Pfizer’s COVID-19 vaccine shows promise, many unknowns remain

It makes sense to bring people to the vaccine instead of taking COVID-19 vaccine to people in some settings: Gagandeep Kang

mRNA vaccines for COVID-19, such as the one developed by Moderna, requires ultralow temperature (-70-80 degree C) during storage. India never had this kind of storage requirement and building the infrastructure for ultracold storage requires considerable resources, as it needs not just the freezers, but also uninterrupted power supply, says Dr. Gagandeep Kang. The government … Continue reading It makes sense to bring people to the vaccine instead of taking COVID-19 vaccine to people in some settings: Gagandeep Kang

India’s potential participation in COVAX advance market commitment is under way: Trevor Mundel

With 11 COVID-19 vaccines having entered Phase-3 trials and six vaccines already approved for limited use, the next challenge is to support manufacturing and ensure that vaccines are accessible, affordable and available to all people. India is yet to agree to purchase COVID-19 vaccines through the COVAX Advance Market Commitment (AMC). Discussions about the terms … Continue reading India’s potential participation in COVAX advance market commitment is under way: Trevor Mundel